The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

Samsung Medical Center

Status and phase: Completed; Phase 4

Conditions: Acute Myocardial Infarction

Treatments: Drug: tirofiban

Study type: Interventional

Funder types: Other

Identifiers

NCT00611169

2005-09-007-001

Details and patient eligibility

About

The purpose of this study to investigate whether the administration of high-dose tirofiban before primary PCI could reduce myocardial infarct size, using analysis of contrast-enhanced magnetic resonance imaging.

Enrollment: 40 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
• ST-segment elevation more than 1 mm in two or more contiguous leads or presumably a new-onset left bundle branch blockage

Exclusion criteria

• hemodynamic instability
• history of MI
• old age > 80years
• Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

1

Experimental group

Description:

Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose

Treatment:

Drug: tirofiban

2

No Intervention group

Description:

Aspirin, clopidogrel, unfractionated heparin